Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Ltd. Statistics
Share Statistics
Alpha Tau Medical Ltd. has 69.92M shares outstanding. The number of shares has increased by 0.36% in one year.
Shares Outstanding | 69.92M |
Shares Change (YoY) | 0.36% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 1.36% |
Shares Floating | 51.62M |
Failed to Deliver (FTD) Shares | 2.55K |
FTD / Avg. Volume | 2.76% |
Short Selling Information
The latest short interest is 67.06K, so 0.1% of the outstanding shares have been sold short.
Short Interest | 67.06K |
Short % of Shares Out | 0.1% |
Short % of Float | 0.13% |
Short Ratio (days to cover) | 3.01 |
Valuation Ratios
The PE ratio is -7.14 and the forward PE ratio is -8.27. Alpha Tau Medical Ltd.'s PEG ratio is 0.34.
PE Ratio | -7.14 |
Forward PE | -8.27 |
PS Ratio | 0 |
Forward PS | 1.6 |
PB Ratio | 2.46 |
P/FCF Ratio | -8.54 |
PEG Ratio | 0.34 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Alpha Tau Medical Ltd..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.07, with a Debt / Equity ratio of 0.16.
Current Ratio | 12.07 |
Quick Ratio | 12.08 |
Debt / Equity | 0.16 |
Total Debt / Capitalization | 13.58 |
Cash Flow / Debt | -1.35 |
Interest Coverage | 914.87 |
Financial Efficiency
Return on equity (ROE) is -0.35% and return on capital (ROIC) is 36.52%.
Return on Equity (ROE) | -0.35% |
Return on Assets (ROA) | -0.27% |
Return on Capital (ROIC) | 36.52% |
Revenue Per Employee | 0 |
Profits Per Employee | -240.97K |
Employee Count | 121 |
Asset Turnover | 0 |
Inventory Turnover | -56.53 |
Taxes
Income Tax | 16K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -0.33% in the last 52 weeks. The beta is 0.84, so Alpha Tau Medical Ltd.'s price volatility has been higher than the market average.
Beta | 0.84 |
52-Week Price Change | -0.33% |
50-Day Moving Average | 3.32 |
200-Day Moving Average | 2.59 |
Relative Strength Index (RSI) | 46.57 |
Average Volume (20 Days) | 92.49K |
Income Statement
Revenue | n/a |
Gross Profit | -1.07M |
Operating Income | 35.68M |
Net Income | -29.16M |
EBITDA | -28.03M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.42 |
Balance Sheet
The company has 12.66M in cash and 13.28M in debt, giving a net cash position of -619K.
Cash & Cash Equivalents | 12.66M |
Total Debt | 13.28M |
Net Cash | -619K |
Retained Earnings | -115.76M |
Total Assets | 90.73M |
Working Capital | 63.44M |
Cash Flow
In the last 12 months, operating cash flow was -17.96M and capital expenditures -6.4M, giving a free cash flow of -24.36M.
Operating Cash Flow | -17.96M |
Capital Expenditures | -6.4M |
Free Cash Flow | -24.36M |
FCF Per Share | -0.35 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
DRTS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -14.05% |
FCF Yield | -11.65% |
Analyst Forecast
The average price target for DRTS is $8, which is 167.6% higher than the current price. The consensus rating is "Buy".
Price Target | $8 |
Price Target Difference | 167.6% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Scores
Altman Z-Score | 2.72 |
Piotroski F-Score | 2 |